RiverPark Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.96M Sell
3,298
-173
-5% -$177K 1.81% 22
2026
Q1
$3.19M Buy
3,471
+38
+1% +$38.5K 1.16% 24
2025
Q4
$3.69M Sell
3,433
-863
-20% -$825K 1.06% 28
2025
Q3
$3.28M Buy
4,296
+220
+5% +$164K 1.42% 18
2025
Q2
$3.18M Buy
4,076
+250
+7% +$194K 1.95% 14
2025
Q1
$3.16M Buy
3,826
+435
+13% +$362K 2.46% 13
2024
Q4
$2.62M Buy
3,391
+375
+12% +$311K 2.09% 15
2024
Q3
$2.67M Buy
3,016
+561
+23% +$504K 2.18% 13
2024
Q2
$2.22M Buy
2,455
+134
+6% +$107K 1.84% 18
2024
Q1
$1.81M Buy
2,321
+310
+15% +$221K 1.48% 24
2023
Q4
$1.17M Buy
2,011
+686
+52% +$400K 1.08% 38
2023
Q3
$712K Buy
+1,325
New +$683K 0.64% 45

Other funds holding LLY

RiverPark Advisors's LLY Position: Q2 2026 in Review

RiverPark Advisors reduced its Eli Lilly (LLY) stake by 5% in Q2 2026, selling an estimated $177K and leaving 3,298 shares worth $3.96M. The position accounts for 1.81% of the portfolio, ranked #22.

RiverPark Advisors first reported a position in LLY in Q3 2023 and has held it in 12 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • RiverPark Advisors held 3,298 shares of Eli Lilly worth $3.96M as of Q2 2026.
  • RiverPark Advisors sold 173 Eli Lilly shares in Q2 2026, an estimated $177K.
  • Eli Lilly made up 1.81% of RiverPark Advisors's portfolio in Q2 2026, its #22 holding.
  • RiverPark Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 12 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on RiverPark Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.